Korea Investment & Securities US
1350 Avenue of the Americas, Suite 1610, New York, NY, 10019, United States
Overview
Korea Investments & Securities Inc. provides a range of financial services including advisory, consultancy, and research. The company operates as a regulated broker-dealer and is a wholly-owned subsidiary of Korea Investment & Securities Co., Ltd. It offers investment banking, sales and trading, wealth management, and ESG services. The firm is involved in various financial products, including acquisition financing.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Advice
- Consulting
- Financial Services
Investment portfolio
- Vedanta Biosciences
Participated · Equity · Apr 2023
Vedanta's lead program, VE303, is an orally administered live biotherapeutic product comprising a defined consortium of eight bacterial strains, developed to prevent recurrent Clostridioides difficile infection. VE303 is produced from pure, clonal bacterial cell banks to yield a standardized powdered drug product and has received FDA Orphan Drug designation (2017) and Fast Track designation (2023). The registrational Phase 3 RESTORATiVE303 trial is randomized, double-blind and placebo-controlled with a 2:1 randomization and a primary endpoint of CDI recurrence rate at Week 8. RESTORATiVE303 is enrolling across more than 150 sites in about 20 countries, has passed a DMC interim analysis recommending continuation, and is expected to complete enrollment in H2 2026 with topline data in H1 2027. Vedanta is funding the trial through the recent $60M financing package and supplemental BARDA funding. The company intends the RESTORATiVE303 study to form the basis for a Biologics License Application to the U.S. FDA.
Team
No current team members are available.